MP22-09 ASSOCIATION BETWEEN ANDROGEN-DEPRIVATION THERAPY AND NON-PROSTATE CANCER MORTALITY AMONG MEN WITH NON-METASTATIC PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Radiation Therapy1 Apr 2018MP22-09 ASSOCIATION BETWEEN ANDROGEN-DEPRIVATION THERAPY AND NON-PROSTATE CANCER MORTALITY AMONG MEN WITH NON-METASTATIC PROSTATE CANCER Christopher Wallis, Raj Satkunasivam, Sender Herschorn, Calvin Law, Arun Seth, Ronald Kodama, Girish Kulkarni, and Robert Nam Christopher WallisChristopher Wallis More articles by this author , Raj SatkunasivamRaj Satkunasivam More articles by this author , Sender HerschornSender Herschorn More articles by this author , Calvin LawCalvin Law More articles by this author , Arun SethArun Seth More articles by this author , Ronald KodamaRonald Kodama More articles by this author , Girish KulkarniGirish Kulkarni More articles by this author , and Robert NamRobert Nam More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.720AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Androgen deprivation therapy (ADT) has been associated with cardiovascular risk factors and the development of cardiovascular disease in men with metastatic prostate cancer. The effect of ADT on non-prostate cancer mortality is unknown among patients with non-metastatic prostate cancer. METHODS We performed a population-based, retrospective cohort study of men treated with surgery or radiotherapy for non-metastatic prostate cancer in Ontario, Canada from 2002-2009. ADT exposure was operationalized as a time-varying binary and cumulative dose exposure. Primary and secondary outcomes were non-prostate cancer mortality and cardiovascular mortality, respectively. The Fine & Gray sub-distribution method with generalized estimating equations was used to calculate sub-distribution hazard ratios (sdHR), while accounting for competing risks. RESULTS We examined 20,651 men treated for non-metastatic prostate cancer. Median follow-up was 7.4 years. Androgen deprivation therapy was not significantly associated with non-prostate cancer mortality (sdHR 0.75, 95% CI 0.37-1.50) or cardiovascular mortality (sdHR 1.16, 95% CI 0.37-3.63) when operationalized as a binary time-varying exposure. Similar results were obtained when we examined ADT cumulative dose exposure. CONCLUSIONS Androgen deprivation therapy is not associated with non-prostate cancer mortality or cardiovascular mortality in a large, population-based cohort of men with localized prostate cancer treated by surgery or radiation therapy. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e274-e275 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Christopher Wallis More articles by this author Raj Satkunasivam More articles by this author Sender Herschorn More articles by this author Calvin Law More articles by this author Arun Seth More articles by this author Ronald Kodama More articles by this author Girish Kulkarni More articles by this author Robert Nam More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...